Researchers use our
technologies in their quest
to cure diseases like cancer,
HIV, and Parkinson’s
mRNA Cell Reprogramming
Conventional reprogramming methods (e.g., using Sendai virus or episomal vectors) can result in very low efficiency reprogramming, can select for cells with abnormal growth characteristics, and can leave traces of the vector in reprogrammed cells.
Our scientists developed a technology for reprogramming cells that uses mRNA to express reprogramming factors2.
mRNA Cell Reprogramming is protected by fourteen U.S. patents, as well as patents in Australia, China, Europe, Japan, Mexico, and Russia (with additional patents pending in the U.S. and in other countries). Of note, certain granted patents include claims that are not limited by disease indication, cell type, reprogramming factor(s), mRNA sequence or chemistry, or method of transfection.
- Ultra-high efficiency reprogramming (e.g., reprogram single cells)
- Reprogram without using viruses or other potentially mutagenic vectors
- Reprogram cells quickly, and using a simple protocol (e.g., 4-6 transfections, pick colonies in 8-12 days)
- Reprogram without feeders, conditioning, passaging, immunosuppressants, demethylating agents or other toxic small molecules, pre-mixing or aliquoting of RNA solutions
- Reprogram using a completely animal component-free process
- Use for the development of allogenic or autologous cell therapies
- Combine with Factor’s Chromatin Context-Sensitive Gene-Editing Endonuclease and/or Factor’s Combined mRNA Gene Editing & Cell Reprogramming technology to generate models of genetic disease, gene-corrected patient-specific cell therapies, and allogeneic (i.e., immuno-nonreactive or “stealth”) cell therapies, including allogeneic pluripotent stem cell-derived CAR-T and CAR-NK cell therapies for the treatment of cancer, and engineered mesenchymal stem cell (MSC) therapies for regenerative medicine, wound-healing, inflammatory and auto-immune diseases, and tumor-targeting applications
2Harris, J., et al. Mol Ther, Vol 28 No 4S1, 2020.
Figure 1. mRNA Cell Reprogramming from biopsy to pluripotent stem cell line.
Figure 2. Characterization of human pluripotent stem cells generated using mRNA Cell Reprogramming.